Oct 27,2023

Lunit Enters into Research Collaboration to Explore the Use of AI to Improve the Effectiveness of Immunotherapy

Lunit announced a research collaboration with The University of Texas MD Anderson Cancer Center to analyze the use of Merck's (known as MSD outside the US and Canada) Keytruda (pembrolizumab), a type of immunotherapy drug used in cancer treatment, in multiple cancer types. The project will use Lunit's proprietary AI solution for tissue data analysis, Lunit SCOPE IO. The goal of the study is to evaluate AI technology with the objective of improving patient data analysis and increasing the effective use of treatment for patients with different types of cancer. Lunit and Dr. Naing team plans to assess Merck's clinical data by leveraging the capabilities of Lunit SCOPE IO, AI software that analyzes H&E-stained tissue slides to enable immune phenotyping and more.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 31,2023 TOP STORY

Guardant Health, Flatiron Health announce integration of Guardant genomic profiling tests into OncoEMR® platform

Guardant Health, a leading precision oncology company, and Flatiron Health announced an initiative to integrate Guardant’s comprehensive genomic profiling tests within Flatiron’s OncoEMR®, a leading cloud-based electronic medical record (EMR) tool. The integration simplifies access to critical data that informs patient care decisions for over 2,000 clinicians within the Flatiron network, which includes more than 800 community-based cancer care locations across the U.S. Users can easily submit Guardant Health test orders, track real-time status updates, and receive the test results directly in the patient record, via the Molecular Profiling Integration on the OncoEMR platform. This streamlines workflows for physicians and saves time in the ordering process. The companies beta-tested the integration at multiple oncology practice sites across the U.S. earlier this year and saw >75% utilization of the integration vs. traditional ordering workflows. Guardant Health and Flatiron Health plan to roll the integration out to the entire OncoEMR network over the next several months.

COLLABORATION PARTNERSHIP

#product & service

#genomic test

View Analyst & Ambassador Comments
Go to original news
Nov 01,2023 TOP STORY

Massive Bio and Health in Code Collaborate to Enhance Personalized Oncology Treatment Through Advanced Genomic Testing

Massive Bio and Health in Code, announced their collaboration, aiming to combine Massive Bio’s Artificial Intelligence (AI) capabilities with Health in Code’s advanced genomic testing. By incorporating biomarker testing and genomic data into clinical decision-making, both organizations aim to provide more accurate and individualized treatments for cancer patients. The core of the collaboration lies in the goal to increase patient access to clinical trials and precision oncology. Integrating Health in Code’s state-of-the-art cancer genetic knowledge and testing capabilities with Massive Bio’s AI-driven prescreening tools are expected to improve health outcomes and significantly reduce costs. This union is promising, especially for patients in Spain, where Health in Code has a significant presence.

COLLABORATION PARTNERSHIP

#data & technology

#ai/software

#genomic test

View Analyst & Ambassador Comments
Go to original news
Oct 27,2023

Skin Cancer Diagnoses Using AI Are as Reliable as those Made by Medical Experts

Artificial intelligence (AI) is already widely used in medical diagnostics. An Austrian-Australian research team led by dermatologist Harald Kittler from MedUni Vienna investigated the extent to which diagnosis and therapy of pigmented skin lesions benefit from it in a realistic clinical scenario. In a study published by The Lancet Digital Health, the team compared the accuracy in diagnosis and therapy recommendation of two different algorithms in smartphone applications with that of doctors. The results show that the AI application generally performs well in diagnosis. However, doctors were clearly superior when it came to treatment decisions.

CLINICAL STUDY

#ai/software

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

Henlius and OncoHost partner to predict trial outcomes using machine learning

Hengenix Biotech (Henlius USA) has partnered with OncoHost to perform biomarker analysis and predict clinical benefit probability in the patients recruited as part of the Phase III clinical trial for serplulimab. OncoHost’s PROphet platform analyses blood samples using aptamer-based assays and applies machine learning models for patient selection, overall survival (OS)/ progression-free survival (PFS) prediction, mechanisms of action discovery, adverse events prediction and response prediction. The PROphet platform will analyse the patients’ biomarkers in the serplulimab Phase III trial (NCT05468489) to identify resistance patterns in the recruited patient population. The open-label Phase III trial compares the efficacy and safety of serplulimab and chemotherapy (carboplatin-etoposide) in combination with the standard of care, atezolizumab plus chemotherapy, in previously untreated US-based patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

COLLABORATION PARTNERSHIP

#institution

#ml

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 26,2023

Philips teams with imaging biomarker specialist Quibim on AI-based imaging and reporting solutions for MR prostate exams

Philips and Quibim will now work on an integrated solution including Quibim’s artificial intelligence (AI) based QP-Prostate software, to automate real-time prostate gland segmentation in MR images, generating meaningful quantitative insights, and standardize MR prostate exam reporting. Combined with Philips’ AI-based MR imaging techniques, the solution aims to provide clinicians with the speed and precision needed to deal with the growing number of patients in need of MR exams to help enhance diagnostic confidence, personalized treatment and better outcomes. Philips MR solutions and Quibim’s QP-Prostate software will be demonstrated in the Philips booth (#6730) and the Quibim Booth (#6336) at the Radiological Society of North America Annual Meeting (RSNA 2023, November 26-29, Chicago, USA).

COLLABORATION PARTNERSHIP

#r&d

#ai/software

View Analyst & Ambassador Comments
Go to original news
Oct 27,2023

Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development

Veracyte announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San Diego from November 3-5 will demonstrate the potential for using the company’s novel tools to help advance the development of immuno-oncology drugs. These tools allow for better characterization of the tumor microenvironment (TME), which can enable new insights into drug response and mechanisms of resistance. The following posters will be presented at the SITC 2023 meeting on Saturday, November 4, 2023: Deciphering the relationship between lymphocytes and macrophages within the tumor micro-environment using a workflow combining RNA transcripts detection and multiplex IHC on Brightplex®; and Regulatory T-cell tumor infiltration improves advanced NSCLC patients’ outcome under ? 2nd line anti-PD1/L1monotherapy in The PIONeeR Project. In addition, Veracyte will host the following corporate symposium on Friday, November 3, 2023, from 5:10 p.m. to 6:40 p.m. PT: A Promising Biomarker of Tumor Immunogenicity: Unveiling the Potential of Immunoscore IC® (CD8/PDL1)

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 23,2023 TOP STORY

Flatiron Health Launches New Strategic Collaboration to Advance Health Insights and Equity of Cancer Care

Flatiron Health today announced a new agreement to bring Flatiron Assist™ advanced cancer care insights to oncology care clinicians at Penn Medicine’s Abramson Cancer Center (ACC). The collaboration between Flatiron Health and Penn Medicine will focus on further enabling clinicians at ACC to determine and promote site-preferred pathways and open clinical trials at the point of care alongside the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Access to evidence-based treatment recommendations will promote high levels of guideline-concordant care, while improving health equity and patient experiences and reducing unnecessary spending. The two organizations will also work together to optimize the usability and functionality of Flatiron Assist™. Flatiron Assist™ is an oncology-specific clinical decision support platform that prioritizes the latest evidence-based medicine, site-preferred pathways and clinical research at the point of care. The EHR-integrated platform incorporates NCCN Guidelines for the 26 most common cancers as well as site-preferred treatment pathways and relevant clinical trial opportunities for patients at the point of care.

COLLABORATION PARTNERSHIP

#institution

#clinical decision support

View Analyst & Ambassador Comments
Go to original news
Aug 23,2023

VOCxi and S3 partner to develop lung cancer detection and monitoring tech

VOCxi Health and S3 Connected Health have entered a partnership agreement to develop and market a lung cancer detection and monitoring device. VOCxi currently has a breath analyser device, BreathEZ, which is designed to detect lung cancer by analysing volatile compounds in the exhaled air. The device is supposed to help in early detection of lung cancer, thereby, improving survival rates for affected patients. S3 Connected has a digital health platform, Affinal, which is designed to better integrate digital services. As per the partnership agreement, VOCxi plans to leverage S3’s Affinal platform to create a custom mobile application and a cloud-based solution for BreathEZ. The companies also plan on expanding the usage of BreathEZ to other disease indications.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Oct 23,2023 TOP STORY

Lucida Medical's New AI Software for Prostate Cancer Diagnosis Received CE Mark Certification

Lucida Medical Ltd, a Cambridge-based start-up company dedicated to improving cancer diagnosis, has announced Class IIb CE certification for its AI-based prostate cancer detection software, Prostate Intelligence™ (Pi™). Built with leading clinicians and UK NHS hospitals, the CE mark means the software can now benefit patients across Europe. Data presented at the European Society for Urogenital Radiology (ESUR) in September 2023 indicated that Pi™ could help cut undetected cancers to 6% while also reducing avoidable biopsies to 43%. Using AI, Pi™ analyses the MRI and is fully integrated into the radiologist's workflow, targeting key issues of variability, radiologist time, and diagnostic accuracy in prostate cancer. Specifically, Pi™ is intended to be used by radiologists to assess and report prostate MRI studies, by automatically producing 3D segmentations, volumes and risk scores. The company plans to make Pi™ commercially available in the UK and EU in Q1, 2024. Pi™ is not for sale in the US.

REGULATORY CE MARK

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY